<DOC>
	<DOCNO>NCT02500849</DOCNO>
	<brief_summary>The purpose study evaluate safety feasibility administer SB-728mR-HSPC conditioning busulfan .</brief_summary>
	<brief_title>Safety Study Zinc Finger Nuclease CCR5-modified Hematopoietic Stem/Progenitor Cells HIV-1 Infected Patients</brief_title>
	<detailed_description>The objective study evaluate safety feasibility give autologous SB-728mR-HSPC HIV-1 ( R5 ) infect patient treated cART undetectable virus suboptimal CD4+ cell level . To strengthen possibility CCR5-disrupted HSPCs engraft , patient receive either two- three-day ( Cohort 1 Cohort 2 ) course busulfan ( dose target AUC 4000 µM/day ) infuse genetically modify cell . At 9-12 month SB-728mR-HSPC infusion , subject aviremic CD4 cell count ≥600 cells/µL ≥1 % CCR5-modified CD4 cell within peripheral blood detect pentamer PCR undergo ATI .</detailed_description>
	<mesh_term>Busulfan</mesh_term>
	<criteria>Maximum age 75 year cohort 1 65 year cohort 2 . HIV1 R5 seropositive evidence CXCR4tropic virus . On cART undetectable HIV1 ( &lt; 20 gc/ml HIV1 RNA ) least 12 month prior screen evaluation . CD4+ Tcell count ≥200 cells/µL ≤750 cells/µL . No psychosocial condition would hinder study compliance followup . Absence clinically significant cardiomyopathy , congestive heart failure . Secondary Eligibility Criteria ( registration ) : Complete GCSF/Plerixafor mobilization HSPC . Collect ≥7.5 x 10^6 CD34+ cells/kg two aphereses . The SB728mRHSPC product pass release test Use AZT maraviroc cART regimen . History significant hematologic disease leukemia , myelodysplasia , coagulopathy , thromboembolism . Any AIDSrelated opportunistic infection occur within past year tuberculosis , cryptococcosis treatment unsuccessful determine Principal Investigator . AIDSrelated syndrome , infectious otherwise , perceive cause excessive risk morbidity postHSPC infusion , determine Principal Investigator . Patients active HBV HCV infection , i.e. , HBV DNA HCV RNA blood , exclude . Those inactive , past infection HBV ( positive HBV surface antigen HBV surface antibody ) inactive HCV ( positive HCV antibody ) , must cirrhosis , determine abdominal ultrasound elastography . Active CMV retinitis active CMVrelated organ dysfunction . CXCR4tropic virus . Pregnant nursing woman . Any history HIVassociated encephalopathy ; dementia kind ; seizure past 12 month ; perceive inability directly provide inform consent . Participants may receive investigational agent , concurrent biological , chemotherapy , radiation therapy . Participation prior investigational drug medical device study within previous 45 day . Current history immunomodulatory agent steroid use . Prior therapy HIV vaccine gene therapy product . History alcohol substance abuse previous 12 month . Participants active malignancy . However , participant skin cancer , namely basal cell squamous cell carcinoma , malignancy treat curative intent know active disease present ≥2 year , may eligible .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Gene therapy</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>HIV Infections</keyword>
	<keyword>Retroviridae Infections</keyword>
	<keyword>RNA Virus Infections</keyword>
	<keyword>Virus Diseases</keyword>
	<keyword>Sexually Transmitted Diseases , Viral</keyword>
	<keyword>Sexually Transmitted Diseases</keyword>
	<keyword>Immunologic Deficiency Syndromes</keyword>
	<keyword>Immune System Diseases</keyword>
	<keyword>Busulfan</keyword>
	<keyword>Pharmacologic Actions</keyword>
</DOC>